Homepage - Ophthalmology Advisor
This Domestic Violence Awareness Month, Psychiatry Advisor spoke with Allison Paugh to discuss best practices when encountering cases of suspected IPV during teletherapy.
Gene Therapy Sustains Acuity in MT-ND4 LHON - Ophthalmology …
1 天前 · A gene therapy, lenadogene nolparvovec, can sustain improvement in best-corrected visual acuity (BCVA) for up to 5 years in patients with MT-ND4 Leber hereditary optic neuropathy (LHON), according to research published in JAMA Ophthalmology.The therapy also demonstrates a favorable safety profile, according to the report.
Intraocular Lens Choice Dependent on Lifestyle, Expectations ...
2024年10月4日 · Cataract surgeons are responsible for advising patients on a decision that will have lifelong implications. Identifying the intraocular lens (IOL) choice most suited for a particular patient’s lifestyle should be done with the patient’s careful consideration, and full understanding of the portfolio of options before them.
FDA Alerts: Ophthalmology Drug and Device Approvals
2024年2月20日 · Drug Regulatory Updates. Susvimo: Diabetic Eye Conditions. The FDA has accepted the application for Susvimo ® (ranibizumab injection, Genentech) to treat diabetic macular edema (DME) and diabetic retinopathy (DR) based on 1-year Pagoda and Pavilion study data. 3 Susvimo is a refillable implant that delivers medication continuously. 3. Based on 2 years of Phase 3 data presented at American ...
Ophthalmology Advisor Redesign: New Look, Better Access, …
Welcome to the new Ophthalmology Advisor! As you can see, we’ve completely redesigned the site with a sleeker, more modern feel to better fit our top-quality and comprehensive eye care coverage.
With Preexisting Corneal Disease, Adjust Cataract Surgery Approach
2023年11月22日 · Cataract surgery is one of the most commonly performed procedures in ophthalmology and results are generally excellent. However, unique challenges can arise when a patient has preexisting corneal disease or has undergone a corneal procedure.
Treatment Burden Reduction in Retinal Care a Prime Focus At AAO ...
2024年11月1日 · It was 20 years ago, not quite today, that the first anti-vascular endothelial growth factor (VEGF) agent was approved for ophthalmic use. 1 And while these drugs did create a whole new paradigm for treating age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal conditions, researchers have not spent the last 20 years resting on their laurels.
Photobiomodulation: An Emerging Dry AMD Treatment
2024年3月20日 · In exudative age-related macular degeneration (wet AMD), significant strides — such as the development of anti-vascular endothelial growth factor (anti-VEGF) therapies — have pushed the treatment possibilities forward and rewritten the likely course of the disease for many patients. However, for most patients, AMD is nonexudative (dry), and treatments for those patients remain largely ...
The Discussion Room Archives - Ophthalmology Advisor
2023年10月16日 · Gloria B. Chiu, OD, optometrist and Associate Professor of Clinical Ophthalmology at the University of Southern California (USC) Roski Eye Institute in Los Angeles, and Annie Nguyen, MD, dry eye specialist, refractive surgeon, and Assistant Professor of Clinical Ophthalmology at the USC Roski Eye Institute, discuss treatment response heterogeneity and novel pharmacologic therapies ...
In Glaucoma Management, Less is More - Ophthalmology Advisor
2021年4月23日 · A riddle stands at the center of glaucoma care. Research indicates that, when intraocular pressure (IOP) is substantially lowered, disease progression can be halted. 1 Yet, multiple studies show that, despite adequate lowering of IOP, disease progression still occurs. 2,3 How do we reconcile this apparent paradox? Why do medicated patients continue to progress despite IOPs that are low enough ...